pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
476
stories
20d
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
21d
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
21d
NIH funding uncertainty thwarts U.S. researchers
stat
21d
STAT+: The fresh faces that may shake up key Senate committees ahead of midterms
stat
21d
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
21d
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data
fiercebiotech
22d
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
biospace
23d
5 biggest venture capital raises of Q3 2026
biospace
23d
Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
fiercebiotech
23d
FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
biospace
23d
The top biopharma conferences in 2027
biopharma dive
24d
FDA delays Novo’s hemophilia A drug review over factory issues
endpoints
24d
STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
stat
24d
How AI is transforming biopharma manufacturing facilities of the future
biopharma dive
27d
What it’s like to wait for the call from the Nobel Prize committee
stat
27d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
27d
STAT+: Up and down the ladder: The latest comings and goings
stat
27d
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
27d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
28d
Mistrust in science and a juicy gene-editing lawsuit
stat
28d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
28d
3 takeaways from a European obesity scientific meeting
biopharma dive
28d
United Therapeutics' legal victory; BMS' Camzyos approved for kids
endpoints
28d
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
28d
#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
endpoints
28d
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
28d
Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drug
endpoints
29d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
29d
The top 12 companies hiring in biopharma now
biospace
29d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
← prev
page 3 of 16
next →
